H S Sader

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi request reprint Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
  2. ncbi request reprint Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
  3. doi request reprint Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus
    Helio S Sader
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 73:212-4. 2012
  4. doi request reprint Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:2558-63. 2016
  5. doi request reprint Ceftaroline activity tested against viridans group streptococci from US hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 84:232-5. 2016
  6. doi request reprint Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 83:389-94. 2015
  7. doi request reprint Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 70:2053-6. 2015
  8. doi request reprint Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:3656-9. 2015
  9. doi request reprint Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 83:379-81. 2015
  10. doi request reprint Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:3263-70. 2015

Collaborators

Detail Information

Publications148 found, 100 shown here

  1. ncbi request reprint Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:281-8. 2002
    ..National and international surveillance programs as a guide to focusing intervention strategies should assist in the control of escalating antimicrobial resistance in this geographic area...
  2. ncbi request reprint Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
    ..The escalating occurrence (0.35%) of serine carbapenemases could compromise the role of carbapenems and other beta-lactams in USA clinical practice although observed in only a few locations to date...
  3. doi request reprint Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus
    Helio S Sader
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 73:212-4. 2012
    ..In summary, daptomycin exhibited species-specific activity among CoNS, especially versus S. sciuri. No correlation between decreased susceptibility to daptomycin and the glycopeptides tested was observed...
  4. doi request reprint Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:2558-63. 2016
    ..9% forS. aureus(95.9% among methicillin-resistantS. aureus[MRSA]), 100.0% for βHS, 86.5% forE. coli, and 89.0% forK. pneumoniae Ceftaroline and tigecycline provided the best overall coverage. ..
  5. doi request reprint Ceftaroline activity tested against viridans group streptococci from US hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 84:232-5. 2016
    ..In summary, ceftaroline exhibited potent in vitro activity against VGS, including many uncommonly isolated species/groups for which very limited susceptibility information is currently available to guide therapy. ..
  6. doi request reprint Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 83:389-94. 2015
    ..5% for cefepime. Ceftazidime-avibactam inhibited 67.4% of isolates at ≤8 μg/mL (MIC(50)/MIC(90), 8/32 μg/mL) that were nonsusceptible to ceftazidime, cefepime, piperacillin-tazobactam, and meropenem...
  7. doi request reprint Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 70:2053-6. 2015
    ..The objective of this study was to evaluate the in vitro antimicrobial activity of ceftaroline and comparator agents tested against Staphylococcus aureus isolates causing bloodstream infection (BSI)...
  8. doi request reprint Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:3656-9. 2015
    ..5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively...
  9. doi request reprint Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 83:379-81. 2015
    ..and Escherichia coli, 55.0 and 53.2% of strains displayed a colistin MIC 2-fold lower than polymyxin B, but polymyxin B was slightly more potent than colistin against strains with decreased susceptibility to either polymyxin. ..
  10. doi request reprint Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:3263-70. 2015
    ..25 to 2 and 1 to 32 μg/ml) and amikacin (MIC50 and MIC90, 1 to 2 and 2 to 32 μg/ml). Arbekacin also demonstrated potent in vitro activity against a worldwide collection of well-characterized MDR Gram-negative and MRSA strains...
  11. doi request reprint Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 46:53-9. 2015
    ..Ceftazidime/avibactam exhibited potent activity against a large collection of Gram-negative organisms from ICU and non-ICU patients and provided greater coverage than currently available β-lactams. ..
  12. doi request reprint Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 83:183-6. 2015
    ..9%), and the most common carbapenemases were KPC-2/3 (85.4%) and VIM-type (12.5%). Only tigecycline (88.6% susceptible) and colistin (73.9%) exhibited good in vitro activity (>70.0%) against CRE strains. ..
  13. doi request reprint Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 82:78-84. 2015
    ..25 μg/mL for both) but limited activity against ESBL phenotype isolates. In summary, ceftaroline exhibited potent in vitro activity against a large collection of bacterial isolates causing CARTI and SSSI in US medical centers...
  14. pmc Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:2458-61. 2015
    ..5 μg/ml, and ceftaroline activity against the most common Enterobacteriaceae species (MIC50, 0.12 μg/ml; 78.9% susceptible) was similar to that of ceftriaxone (MIC50, ≤0.25 μg/ml; 86.8% susceptible). ..
  15. doi request reprint Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 69:2713-22. 2014
    ..Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor...
  16. doi request reprint Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA Electronic address
    J Infect 69:266-77. 2014
    ..MIC50/90, 0.5/1-2 mg/L). In summary, ceftolozane/tazobactam demonstrated potent in vitro activity when tested against contemporary aerobic Gram-negative pathogens causing IAI and HCA-UTI in USA and European medical centers...
  17. doi request reprint Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012)
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:465-9. 2014
    ..06/0.25 mg/L; 100.0% susceptible). In conclusion, daptomycin has remained very active against indicated species worldwide, and no significant year-to-year or regional variation in daptomycin activity has been detected...
  18. doi request reprint Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:328-34. 2014
    ..were noted in EMR. These results confirm that very few agents remain broadly active against the most frequently isolated Gram-negative organisms from patients with pneumonia in US and EMR medical centres. ..
  19. doi request reprint Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011)
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Ste A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:284-6. 2014
    ..03 mg/L and from ≤ 0.015 mg/L to 0.5mg/L, respectively. Based on these in vitro findings, ceftaroline may have a potential role in the treatment of infections caused by these rarer species as guided by reference MIC test results...
  20. doi request reprint Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA Electronic address
    Diagn Microbiol Infect Dis 78:443-8. 2014
    ..The results of this study (101 medical centers) highlight major antimicrobial coverage problems and trends in antimicrobial resistance for USA and EU ICU patient isolates. ..
  21. pmc Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010
    Rayo Morfin-Otero
    Instituto de Patología Infecciosa y Experimental, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Calle Hospital 308, Colonia El Retiro, CP 44280, Guadalajara, Jalisco, Mexico
    BMC Res Notes 5:277. 2012
    ..The information obtained from antimicrobial resistant programs from two hospitals from Mexico will be helpful in the selection of empiric therapy for hospital-acquired gram-negative infections...
  22. pmc Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:3178-81. 2013
    ....
  23. doi request reprint Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 76:217-21. 2013
    ..3-98.3% inhibited at ≤2 μg/mL). In summary, tigecycline has sustained potent activity and a broad-spectrum against clinically important bacteria causing infections worldwide, including multidrug-resistant organism subsets...
  24. doi request reprint Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, 52317, USA
    Diagn Microbiol Infect Dis 76:61-8. 2013
    ..06/0.12 μg/mL). In summary, ceftaroline showed potent in vitro activity against a large collection of bacterial isolates (2351) associated with SSTI and CARTI from the Asia-Pacific region and South Africa...
  25. pmc Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:1982-8. 2013
    ..Ceftaroline-avibactam was also active against ceftriaxone-nonsusceptible Streptococcus pneumoniae (MIC(90), 0.25 μg/ml) and methicillin-resistant Staphylococcus aureus (MIC(90), 1 μg/ml)...
  26. doi request reprint Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:417-22. 2013
    ....
  27. doi request reprint Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S181-6. 2012
    ..The results also indicate that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independent of patient age group...
  28. doi request reprint Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 67:1170-5. 2012
    ..We evaluated the activity of BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)...
  29. pmc Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:1619-23. 2012
    ..12/2 μg/ml). Compared with other antibiotics in use for the treatment of ABSSSI, BC-3781 displayed the lowest MICs and only a minimal potential for cross-resistance with other antimicrobial classes...
  30. pmc Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients
    Maria Cecilia S Freitas
    Department of Medicine, Division of Nephrology, Universidade Federal de Sao Paulo, Hospital do Rim e Hipertensao, Brazil
    BMC Infect Dis 6:133. 2006
    ..The first reports of VRE isolation were from hemodialysis patients. However, to date, VRE fecal colonization rates as well as associated risk factors in kidney transplant patients have not yet been established in prospective studies...
  31. ncbi request reprint In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 17:622-7. 2005
    ..aeruginosa (IMP-16 and SPM-1-producing strains) and one A. baumannii (non-MbetaL) strain. All other strains showed indifferent interaction (variation of +/- 1 log10 CFU/ml) with any combination evaluated...
  32. pmc Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1153-5. 2008
    ..All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114...
  33. pmc Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
    ..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
  34. ncbi request reprint In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:27-32. 2007
    ....
  35. pmc Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Clin Microbiol 45:1640-3. 2007
    ..Listed modifications were recently approved by the CLSI (M100-S17)...
  36. ncbi request reprint Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:5S-12S. 2007
    ....
  37. ncbi request reprint Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Expert Rev Anti Infect Ther 5:29-43. 2007
    ..g., macrolides, penicillins, tetracyclines, fluoroquinolones and trimethoprim-sulfamethoxazole)...
  38. ncbi request reprint Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:341-4. 2007
    ....
  39. ncbi request reprint Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:329-32. 2005
    ..Resistance to oxacillin or vancomycin did not influence daptomycin activity against S. aureus or E. faecalis...
  40. ncbi request reprint Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:477-83. 2005
    ..The results of this study showed that daptomycin continues to be very active against clinical isolates of Gram-positive cocci isolated in Europe and Latin America...
  41. ncbi request reprint Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)
    H S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 12:844-52. 2006
    ..This novel lipopeptide (daptomycin) appears to be an excellent alternative therapeutic option for serious infections caused by multidrug-resistant gram-positive organisms isolated in Europe...
  42. pmc Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 50:2330-6. 2006
    ....
  43. pmc Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Clin Microbiol 44:1101-4. 2006
    ..aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors...
  44. ncbi request reprint Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 20:28-32. 2008
    ..Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection...
  45. doi request reprint Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Int J Infect Dis 13:291-5. 2009
    ..In the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations...
  46. doi request reprint Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 62:460-3. 2008
    ..No error was observed when levofloxacin was selected as the group surrogate for pneumococcal testing...
  47. doi request reprint Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Diagn Microbiol Infect Dis 70:412-6. 2011
    ..faecium) were detected. In conclusion, daptomycin demonstrated sustained activity against an extensive collection of clinical isolates of MRSA and VRE from numerous US medical centers over the last 6 monitored years...
  48. pmc Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 55:2390-4. 2011
    ..CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains...
  49. doi request reprint Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 69:223-7. 2011
    ....
  50. doi request reprint Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 36:28-32. 2010
    ....
  51. doi request reprint Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 66:329-31. 2010
    ..In conclusion, S. aureus strains with vancomycin MIC of 2 microg/mL showed high rates of hVISA and vancomycin tolerance. Daptomycin retained potent bactericidal activity against S. aureus with decreased susceptibility to vancomycin...
  52. ncbi request reprint Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals
    H S Sader
    JMI Laboratories, North, Liberty, Iowa 52317, USA
    J Chemother 21:611-20. 2009
    ..6% susceptible). In summary, daptomycin and linezolid showed excellent in vitro activity against Gram-positive organisms (12,324) collected in Latin American hospitals, including MRSA, VRE and other multidrug-resistant organisms...
  53. ncbi request reprint Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007)
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 21:500-6. 2009
    ..aureus, coagulase-negative staphylococci, E. faecalis and E. faecium, respectively. Daptomycin activity was not adversely influenced by resistance to oxacillin among staphylococci or to vancomycin among enterococci...
  54. doi request reprint Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:158-62. 2009
    ....
  55. doi request reprint Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 64:1024-8. 2009
    ..The bactericidal activities of vancomycin and daptomycin were evaluated in a large collection of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia strains from nine major USA medical centres...
  56. pmc Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:4127-32. 2009
    ..02 mug/ml). The occurrence of isolates for which the vancomycin MIC was >1 microg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100)...
  57. pmc Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:3162-5. 2009
    ..2% of MRSA isolates) would be categorized as vancomycin nonsusceptible by the MIC results from the Etest method if the susceptibility breakpoint was adjusted downward to < or =1 microg/ml, as suggested by clinical outcome studies...
  58. pmc Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:2171-5. 2009
    ..aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA...
  59. ncbi request reprint Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients
    H S Sader
    JMI Laboratories, North Libtery, Iowa 52314, USA
    J Chemother 20:570-6. 2008
    ..These results indicate that daptomycin has an appropriate spectrum and potency to be used for empirical coverage of Gram-positive infections (especially BSI) in cancer patients in the hospitals surveyed in the USA...
  60. ncbi request reprint Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009)
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 23:200-6. 2011
    ..Decreases in daptomycin potency were not observed since EMEA approval and widespread clinical use, and emerging resistance to other compounds did not adversely influence daptomycin activity against contemporary Gram-positive species...
  61. ncbi request reprint Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:201-4. 2004
    ..Daptomycin showed a significant potency and spectrum against Gram-positive species, including multidrug-resistant strains, and may represent a reasonable therapeutic option for infections caused by these important pathogens...
  62. ncbi request reprint Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:380-4. 2005
    ..The role of combination antimicrobial therapy in the treatment of severe infections caused by multidrug-resistant P. aeruginosa and Acinetobacter spp. should be further evaluated to maximize favourable clinical outcomes...
  63. ncbi request reprint Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:361-4. 2003
    ..8%-91.7%). Continued resistance surveillance by various programs remain necessary to monitor the in vitro effectiveness of antimicrobial agents currently used in clinical practice...
  64. ncbi request reprint Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli
    Helio S Sader
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:95-109. 2005
    ....
  65. ncbi request reprint Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 47:515-25. 2003
    ..These rates of increased susceptibility could sustain and enhance the clinical activity of orally administered beta-lactams such as cefdinir...
  66. pmc Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity
    Helio S Sader
    The JONES Group JMI Laboratories, Inc, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 48:3112-8. 2004
    ..Kill curve experiments showed a clear pattern of bactericidal activity...
  67. ncbi request reprint SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001
    Helio S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 8:25-79. 2004
    ..This report allows the evaluation of the activities numerous antimicrobial agents against clinical isolates collected in Latin American countries...
  68. ncbi request reprint IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital
    H S Sader
    Laboratorio Alerta e Laboratorio Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Microbiol Infect 11:73-6. 2005
    ..MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes...
  69. ncbi request reprint Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Helio S Sader
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
    Int J Antimicrob Agents 25:57-61. 2005
    ..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
  70. ncbi request reprint Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections
    Helio S Sader
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:89-92. 2005
    ..The cefdinir spectrum and potency were comparable or superior to other orally administered beta-lactams tested against recent (2003) clinical isolates from CA-UTI...
  71. pmc Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 49:3501-12. 2005
    ....
  72. ncbi request reprint Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:514-20. 2007
    ..1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries...
  73. ncbi request reprint Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:265-73. 2005
    ..Continued resistance surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime...
  74. ncbi request reprint Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:283-7. 2004
    ..Only 0.5% of all 415 recent CA-SSTI pathogens were resistant to cefdinir (MIC, > or = 4 mg/L). Cefdinir showed a spectrum and potency comparable or superior to other orally administered beta-lactams (cephalexin)...
  75. ncbi request reprint Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program
    H S Sader
    Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:200-14. 2001
    ..Thus, regional surveillance programs are essential to guide empirical therapy and infection control measures...
  76. ncbi request reprint Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)
    H S Sader
    Federal University of Sao Paulo, Medical School of Medecine, Sao Paulo, Sao Paulo, Brazil
    Braz J Infect Dis 4:245-54. 2000
    ..The newer fluoroquinolones show an excellent potency and spectrum against pathogens causing community acquired respiratory infections in Latin America...
  77. ncbi request reprint Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections
    M A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Chemother 22:304-11. 2010
    ..03/0.06 mg/l; 100.0% susceptible). These in vitro data document the activity of telavancin against contemporary Gram-positive isolates and support its clinical use for the treatment of cSSSI caused by the indicated pathogens...
  78. ncbi request reprint Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999
    A C Gales
    University of Iowa College of Medicine, Iowa City, Iowa, USA, and Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Clin Infect Dis 32:S104-13. 2001
    ..maltophilia isolates observed in this study emphasize the importance of local surveillance in determining the most adequate therapy for acinetobacter and S. maltophilia infections and the possible clonal, epidemic nature of occurrence...
  79. ncbi request reprint Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000
    I A Critchley
    Focus Technologies, Inc, Herndon, Virginia, 20171 4603, USA
    Braz J Infect Dis 5:294-304. 2001
    ..Pneumoniae...
  80. ncbi request reprint In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals
    J C Cordeiro
    Special Clinical Microbiology Laboratory, Division of Infectious Diseases, , SP, Brazil
    Braz J Infect Dis 5:130-5. 2001
    ....
  81. ncbi request reprint Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
    Braz J Infect Dis 5:171-6. 2001
    ..The excellent in vitro Gram-positive activity by linezolid, in this study, indicate that this compound may represent an important therapeutic option for the treatment of infections caused by these pathogens in Brazil...
  82. ncbi request reprint Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
    Jennifer M Streit
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:307-10. 2005
    ..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
  83. ncbi request reprint Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam
    H S Sader
    Special Clinical Microbiology Laboratory, Department of Infectious and Parasitic Diseases, Universidade Federal de Sao Paulo, Brazil
    Braz J Infect Dis 4:22-8. 2000
    ..3% to 98.2% susceptibility). In sum, piperacillin/tazobactam was more active against all Gram-negative species than the other two combinations, with the exception of A. baumannii, and showed similar activity against Gram-positive cocci...
  84. ncbi request reprint Screening of antibacterial extracts from plants native to the Brazilian Amazon Rain Forest and Atlantic Forest
    I B Suffredini
    Laboratório de Extração, Universidade Paulista, Sao Paulo, SP, Brasil
    Braz J Med Biol Res 37:379-84. 2004
    ..The most active fractions are being fractionated to identify their active substances. Higher concentrations of other extracts are currently being evaluated against the same microorganisms...
  85. pmc Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
    M A Pfaller
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa, USA
    Antimicrob Agents Chemother 44:747-51. 2000
    ..4 to 100% susceptible). Isolates from Canada and Latin America were generally more susceptible to both triazoles than U.S. isolates were. Continued surveillance appears necessary to detect these important changes...
  86. ncbi request reprint Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program
    D M Johnson
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:373-6. 2003
    ..It is apparent from this investigation that many commonly prescribed empiric treatments remain viable therapeutic options for CARTI caused by these two Gram-negative respiratory tract pathogens...
  87. ncbi request reprint Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program
    A C Gales
    Universidade Federal de Sao Paulo, Division of Infectious Diseases, Department of Medicine, Sao Paulo, Brazil
    J Chemother 16:323-8. 2004
    ..5%) and varied widely (10.0 to 48.9%) among the monitored Latin American medical centers. Mupirocin resistance rates appear to be increasing and routine monitoring for potential resistance seems prudent...
  88. ncbi request reprint Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)
    Ana C Gales
    Division of Infectious Diseases, Universidade Federal de, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:289-99. 2002
    ..Carbapenem-resistant P. aeruginosa, ciprofloxacin-resistant E. coli, ESBL-producing K. pneumoniae constitute serious problem in this geographic region...
  89. ncbi request reprint Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Rodrigo E Mendes
    Special Laboratory of Clinical Microbiology Federal University of São Paulo, SP, Brazil
    Braz J Infect Dis 7:282-9. 2003
    ....
  90. ncbi request reprint Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
    Helio S Sader
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 44:273-80. 2002
    ..In summary, resistance to most antimicrobial agents for a number of species implicated in bacteremia, especially among Gram-negative rods, has reached worrisome levels and continues to increase...
  91. doi request reprint Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:440-6. 2009
    ....
  92. ncbi request reprint Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol
    R N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Chemother 17:593-600. 2005
    ..This high volume international survey indicates potential therapeutic roles for dalbavancin against many troublesome resistant Gram-positive phenotypes...
  93. ncbi request reprint Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study
    H S Sader
    Division of Infectious Diseases, Federal University of Sao Paulo, Rua Botucatu, 740, Sao Paulo SP, 04023 063 Brazil
    Braz J Infect Dis 5:21-31. 2001
    ..These results define the role of quinupristin/dalfopristin in Latin American medical centers and provide a benchmark for future in vitro comparisons...
  94. ncbi request reprint Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection
    A R Marra
    Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Disciplina de Doencas Infecciosas e Parasitarias, Rua Botucatu, 743, 7 andar, Vila Clementino, CEP 04023 062, Sao Paulo, SP, Brazil
    Int J Infect Dis 10:56-60. 2006
    ..For hospitals with a high prevalence of strains producing this enzyme, there is no reference material to show whether the use of the E-test method for their detection, which can be quite expensive, is actually required...
  95. ncbi request reprint Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Jennifer M Streit
    The JONES Group JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
    Int J Antimicrob Agents 24:111-8. 2004
    ..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
  96. ncbi request reprint Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:157-64. 2006
    ..Although resistance has emerged in many epidemiologically distinct strains, clonal dissemination seems to be a key contributing factor for increasing resistance to fluoroquinolones among pneumococci in this nation...
  97. ncbi request reprint In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America
    Ana C Gales
    Department of Medicine, Division of Infectious Diseases, University of Sao Paulo, Rua Leandro Dupret 188, Sao Paulo, Brazil
    Braz J Infect Dis 9:348-56. 2005
    ..The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents...
  98. ncbi request reprint Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004)
    P R Rhomberg
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:459-69. 2005
    ....
  99. ncbi request reprint Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002
    C Mendes
    Fleury Medical Diagnostic Centre, Sao Paulo, Brazil
    Clin Microbiol Infect 10:521-6. 2004
    ..Levofloxacin, a fluoroquinolone prescribed widely for respiratory tract infections, continued to show potent activity against key respiratory pathogens...
  100. ncbi request reprint In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals
    A O Reis
    Division of Infectious Diseases, , Rua Botucatu 740, , SP 04023-063, Brazil
    Braz J Infect Dis 5:243-51. 2001
    ..faecium and E. faecalis among Brazilian hospitals. The results of this study indicate that linezolid is an appropriate therapeutic option for the treatment of vancomycin-resistant enterococci infections in Brazil...
  101. ncbi request reprint Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
    Paul R Rhomberg
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:273-81. 2004
    ..and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients...